ATE127117T1 - 1-aryl-1-hydroxy-1-substituierte-3-(4- substituierte-1-piperazinyl)-2-propanone und ihre verwendung bei der behandlung von blasenstörungen neurologischen ursprungs. - Google Patents

1-aryl-1-hydroxy-1-substituierte-3-(4- substituierte-1-piperazinyl)-2-propanone und ihre verwendung bei der behandlung von blasenstörungen neurologischen ursprungs.

Info

Publication number
ATE127117T1
ATE127117T1 AT90312632T AT90312632T ATE127117T1 AT E127117 T1 ATE127117 T1 AT E127117T1 AT 90312632 T AT90312632 T AT 90312632T AT 90312632 T AT90312632 T AT 90312632T AT E127117 T1 ATE127117 T1 AT E127117T1
Authority
AT
Austria
Prior art keywords
substituted
phenyl
alkyl
carbons
hydroxy
Prior art date
Application number
AT90312632T
Other languages
English (en)
Inventor
Daniel Wilbur Mcpherson
John Paul Carter
Original Assignee
Marion Merrell Dow Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marion Merrell Dow Inc filed Critical Marion Merrell Dow Inc
Application granted granted Critical
Publication of ATE127117T1 publication Critical patent/ATE127117T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
AT90312632T 1988-04-28 1990-11-20 1-aryl-1-hydroxy-1-substituierte-3-(4- substituierte-1-piperazinyl)-2-propanone und ihre verwendung bei der behandlung von blasenstörungen neurologischen ursprungs. ATE127117T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18764988A 1988-04-28 1988-04-28
US07/372,009 US5001160A (en) 1988-04-28 1989-06-27 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
ZA909350A ZA909350B (en) 1988-04-28 1990-11-21 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
AU67005/90A AU634604B2 (en) 1988-04-28 1990-11-26 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1- piperazinyl-2-propanones and their use in treatment of neurogenic bladder disorders

Publications (1)

Publication Number Publication Date
ATE127117T1 true ATE127117T1 (de) 1995-09-15

Family

ID=40149700

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90312632T ATE127117T1 (de) 1988-04-28 1990-11-20 1-aryl-1-hydroxy-1-substituierte-3-(4- substituierte-1-piperazinyl)-2-propanone und ihre verwendung bei der behandlung von blasenstörungen neurologischen ursprungs.

Country Status (9)

Country Link
US (1) US5001160A (de)
EP (1) EP0486734B1 (de)
JP (1) JPH0764833B2 (de)
AT (1) ATE127117T1 (de)
AU (1) AU634604B2 (de)
CA (1) CA2030397C (de)
DE (1) DE69022058T2 (de)
ES (1) ES2079449T3 (de)
ZA (1) ZA909350B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001160A (en) * 1988-04-28 1991-03-19 Marion Laboratories, Inc. 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
NZ329847A (en) * 1996-06-29 1999-01-28 Samjin Pharm Co Ltd Piperazine derivatives and process for the preparation thereof
US6482837B1 (en) 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
JP2004043433A (ja) * 2002-04-26 2004-02-12 Kitai Kagi Kofun Yugenkoshi モルフォリノケトン誘導体及びその用途
AU2002345266B2 (en) 2002-07-08 2009-07-02 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
WO2004064789A2 (en) * 2003-01-16 2004-08-05 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EA009387B1 (ru) * 2003-04-11 2007-12-28 Рэнбакси Лабораториз Лимитед Азабициклические производные в качестве антагонистов мускаринового рецептора
EP1765809B1 (de) * 2004-06-16 2008-12-31 Ranbaxy Laboratories Limited Als antagonisten des muscarinrezeptors geeignete xanthinderivate
EP1781607A2 (de) * 2004-08-19 2007-05-09 Ranbaxy Laboratories Limited Pyrrolidinderivate als antagonisten des muscarinrezeptors
EP1794161A2 (de) * 2004-09-24 2007-06-13 Ranbaxy Laboratories Limited Antagonisten des muskarinrezeptors
EP1797040A1 (de) * 2004-09-29 2007-06-20 Ranbaxy Laboratories Limited Muscarin-rezeptor-antagonisten
WO2006054162A1 (en) * 2004-11-19 2006-05-26 Ranbaxy Laboratories Limited Azabicyclic muscarinic receptor antagonists
WO2006064304A1 (en) * 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
EP1888525A1 (de) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituierte azabicyclo[3.1.0]hexanderivate als antagonisten des muskarinrezeptors
RU2008119323A (ru) 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Фармацевтические композиции мускаринового рецептора
US20090010923A1 (en) * 2007-04-24 2009-01-08 University Of Maryland, Baltimore Treatment of cancer with anti-muscarinic receptor agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125577A (en) * 1964-03-17 N-substttuted piperazinoalkyl
US2835676A (en) * 1953-07-14 1958-05-20 Merck & Co Inc Gamma-keto-tertiary amines and derivatives thereof
US3073842A (en) * 1957-07-22 1963-01-15 Endo Lab 1, 1 diphenyl-1-hydrocarbonoxy, 4-tertiary amino 2-butanones
US3157656A (en) * 1960-07-20 1964-11-17 Olin Mathieson Heterocyclic compounds
US3073854A (en) * 1960-11-28 1963-01-15 California Research Corp Trimethyllead methyl thioglycolate
US3395146A (en) * 1965-02-11 1968-07-30 Warner Lambert Pharmaceutical 4-substituted-2-benzhydryl-2-butanol derivatives
US3873546A (en) * 1974-02-06 1975-03-25 Abbott Lab Catalytic reduction of 4-methyl-{62 ,{62 -diphenyl-1-piperazine ethanol
NL8202636A (nl) * 1982-06-29 1984-01-16 Gist Brocades Nv Piperazinederivaten, werkwijzen ter bereiding daarvan en farmaceutische preparaten die deze verbindingen bevatten.
US5001160A (en) * 1988-04-28 1991-03-19 Marion Laboratories, Inc. 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders

Also Published As

Publication number Publication date
ES2079449T3 (es) 1996-01-16
EP0486734A1 (de) 1992-05-27
DE69022058T2 (de) 1996-04-25
ZA909350B (en) 1991-09-25
CA2030397A1 (en) 1992-05-21
AU6700590A (en) 1992-06-11
JPH0764833B2 (ja) 1995-07-12
EP0486734B1 (de) 1995-08-30
DE69022058D1 (de) 1995-10-05
CA2030397C (en) 1996-06-11
JPH05125068A (ja) 1993-05-21
AU634604B2 (en) 1993-02-25
US5001160A (en) 1991-03-19

Similar Documents

Publication Publication Date Title
ATE127117T1 (de) 1-aryl-1-hydroxy-1-substituierte-3-(4- substituierte-1-piperazinyl)-2-propanone und ihre verwendung bei der behandlung von blasenstörungen neurologischen ursprungs.
NZ240676A (en) Heterocyclic compounds substituted by a (piperidin-4-yl)-1-oxoalkyl group and pharmaceutical compositions thereof
ES476305A1 (es) Un procedimiento para la preparacion de nuevos derivados aminicos
BG105271A (bg) Производни на 1h-имидазопиридин
DE3686248D1 (de) Piperidinderivat, seine verwendung und diese enthaltende pharmazeutische zusammensetzung.
UA26427A (uk) Похідhі ксаhтиhу у вигляді суміші ізомерів або іhдивідуальhих ізомерів, що мають властивість аhтагоhіста адеhозиhу
NO985864L (no) Nye anti-virale forbindelser
ATE173256T1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
BG103426A (en) Derivatives of substituted 4-biphenyl-4-hydroxy-oil acids as inhibitors of matrix metalloproteases
DE3877386D1 (de) Antikrebsverbindungen.
ES463803A1 (es) Procedimiento para la produccion de hidroxilaminas o-alqui- ladas.
ATE109770T1 (de) Derivate der coffeinsäure und pharmazeutische zusammensetzungen, die sie enthalten.
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
MY137964A (en) Benzofuran derivative
EP0335979A4 (en) Thienopyrimidine derivatives
FR2479219B1 (de)
ATE25083T1 (de) Aminopropanolderivate von substituierten 2hydroxy-propiophenonen, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
HUT69392A (en) Alkylenediamine derivatives, pharmaceutical compositions containing them and process for their preparation
FR2652084B1 (fr) Nouveaux derives de la phenothiazine, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB2014561A (en) Amine derivatives, their preparation and pharmaceutical compositions containing them
ES454285A1 (es) Procedimiento para preparar derivados de 4-amina trans-deca-hidroquinolina.
DE3463270D1 (en) Pyridine-pyrimidinone derivatives, process for their preparation and medicines containing these compounds
ATE143591T1 (de) Verwendung von bis-(p- hydroxyphenylthio)methanderivaten zur hemmung der fortschreitenden entwicklung von insulinabhängingem diabetes mellitus
ES2011831A6 (es) Procedimiento para preparar derivados de 1,3-dioxolano y de 1,3-dioxano sustituidos.
TH1208A (de)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee